Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a Phase 1b clinical study titled ‘A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy.’ The study aims to assess the safety and tolerability of the drug Xaluritamig in adults with high-risk biochemical recurrent nonmetastatic castration-sensitive prostate cancer, a condition that poses significant health risks.
The intervention being tested is Xaluritamig, an experimental drug administered as a short-term intravenous infusion over six cycles, each lasting 28 days. The purpose of this treatment is to manage prostate cancer that has recurred biochemically but has not metastasized.
The study is designed as an interventional trial with a single-group model. It is open-label, meaning there is no masking, and its primary purpose is treatment-focused. This straightforward design allows for direct observation of the drug’s effects on participants.
The study began on August 13, 2024, with primary completion anticipated soon. The latest update was submitted on September 10, 2025. These dates are crucial as they mark the progression and current status of the trial.
This study update could influence Amgen’s stock performance positively, as successful results may enhance investor confidence and market position. The prostate cancer treatment market is competitive, with various companies vying for breakthroughs, making Amgen’s progress particularly noteworthy.
The study is ongoing, with further details available on the ClinicalTrials portal.